NVCT Stock Overview
A biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Nuvectis Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.60 |
| 52 Week High | US$12.10 |
| 52 Week Low | US$5.85 |
| Beta | 0.45 |
| 11 Month Change | 13.43% |
| 3 Month Change | 13.10% |
| 1 Year Change | -17.30% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 133.85% |
Recent News & Updates
Recent updates
We Think Nuvectis Pharma (NASDAQ:NVCT) Needs To Drive Business Growth Carefully
Jun 26
Is Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?
Jan 06Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation
Oct 03We're Not Very Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate
Jan 31Nuvectis Pharma forms scientific advisory board for research and development of drugs
Sep 28Nuvectis Pharma GAAP EPS of -$0.28 misses by $0.04
Aug 05Nuvectis Pharma declines 13%, announces $15.9M private placement
Jul 27We're Keeping An Eye On Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate
May 04Shareholder Returns
| NVCT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 18.8% | 0.6% | 0.8% |
| 1Y | -17.3% | 27.4% | 38.3% |
Return vs Industry: NVCT underperformed the US Biotechs industry which returned 26.9% over the past year.
Return vs Market: NVCT underperformed the US Market which returned 36% over the past year.
Price Volatility
| NVCT volatility | |
|---|---|
| NVCT Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NVCT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NVCT's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 13 | Ron Bentsur | www.nuvectis.com |
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company’s lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases.
Nuvectis Pharma, Inc. Fundamentals Summary
| NVCT fundamental statistics | |
|---|---|
| Market cap | US$126.09m |
| Earnings (TTM) | -US$21.10m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.7x
P/E RatioIs NVCT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVCT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$21.10m |
| Earnings | -US$21.10m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.13 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NVCT perform over the long term?
See historical performance and comparison